BrainStorm's NurOwn granted Fast Track for ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) said FDA granted Fast Track designation to its cell-based NurOwn to treat ALS. NurOwn comprises autologous mesenchymal stromal cells induced to differentiate into neurotrophic factor-secreting cells. The therapy has Orphan Drug designation in the U.S. and EU and is in Phase II testing in the indication.

The company did not respond to questions about when it expects Phase II data. ...